Effects of Red Ginseng Upon Postoperative Immunity and Survival in Patients with Stage III Gastric Cancer

American Journal of Chinese Medicine - Tập 30 Số 04 - Trang 483-494 - 2002
Soon Yong Suh1, Matthew Kroh2, Nam Ryeol Kim1, Yong Geul Joh1, Min Young Cho1
1Department of Surgery, Korea University College of Medicine, 126-1 5th-Ga, Anam-Dong Sungbuk-Gu, Seoul, 136–705, Korea
2Mount Sinai School of Medicine, 1 Gustave Levy Place, NYC, NY 10029, USA

Tóm tắt

In this paper, we present evidence that the red ginseng powder from Panax ginseng C.A. Meyer inhibits the recurrence of AJCC stage III gastric cancer and shows immunomodulatory activities during postoperative chemotherapy, after a curative resection with D2 lymph node dissection. Flow cytometric analyses for peripheral T-lymphocyte subsets showed that the red ginseng powder restored CD4 levels to the initial preoperative values during postoperative chemotherapy. Depression of CD3 during postoperative chemotherapy was also inhibited by the red ginseng powder ingestion. This study demonstrated a five-year disease free survival and overall survival rate that was significantly higher in patients taking the red ginseng powder during postoperative chemotherapy versus control (68.2% versus 33.3%, 76.4% versus 38.5%, respectively, p < 0.05). In spite of the limitation of a small number of patients (n = 42), these findings suggest that red ginseng powder may help to improve postoperative survival in these patients. Additionally, red ginseng powder may have some immunomodulatory properties associated with CD3 and CD4 activity in patients with advanced gastric cancer during postoperative chemotherapy.

Từ khóa


Tài liệu tham khảo

10.1002/jso.2930450302

American Joint Committee on Cancer, 1997, Philadelphia, 71

10.1136/pgmj.64.757.841

10.1002/1097-0142(19840401)53:7<1484::AID-CNCR2820530710>3.0.CO;2-T

10.3346/jkms.1995.10.3.164

10.1023/A:1018491314066

Kaszubowski P.A., 1980, Cancer Res., 40, 4648

Kenarova B., 1990, Jpn. J. Pharmacol., 54, 454

10.1055/s-2006-957385

10.3109/08923979009019672

Klein C., 2000, J. Gastroenterol., 35, 1

10.1016/S0303-7207(97)00160-3

Lee Y.S., 1997, Anticancer Res., 17, 323

10.1007/BF00685902

10.1248/cpb.37.1279

10.1248/bpb.18.1197

10.1016/0014-2964(79)90230-5

10.1248/bpb.17.635

10.1016/S0162-3109(96)00125-7

10.1002/jso.2930350403

10.1038/sj.onc.1201640

10.1159/000226852

Tsubono M., 1990, J. Clin. Lab. Immunol., 33, 107

10.1002/jso.2930490310

van Rocnn J., 1987, J. Clin. Oncol., 5, 150, 10.1200/JCO.1987.5.1.150

Wakabayashi C., 1998, Biol. Pharm. Bull., 246, 725

10.1016/S0378-8741(97)00133-5

Yun T.K., 1998, Int. J. Epidemiol., 27, 364

Yun T.K., 1995, Cancer Epidemiol. Biomarkers Prev., 4, 401

Yun Y.S., 1987, Cancer Detect. Prev., 1, 301